|
1
|
Müller A, Homey B, Soto H, Ge N, Catron D,
Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al:
Involvement of chemokine receptors in breast cancer metastasis.
Nature. 410:50–56. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
DeSantis C, Siegel R, Bandi P and Jemal A:
Breast cancer statistics, 2011. CA Cancer J Clin. 61:408–418. 2011.
View Article : Google Scholar
|
|
4
|
DiSipio T, Rye S, Newman B and Hayes S:
Incidence of unilateral arm lymphoedema after breast cancer: A
systematic review and meta-analysis. Lancet Oncol. 14:500–515.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Charif M, Lower EE, Kennedy D, Kumar H,
Khan S, Radhakrishnan N and Zhang X: Abstract P3-05-16: The effect
of HER-2/neu inhibition on prolonging clinical benefit with
fulvestrant treatment for metastatic estrogen receptor positive
breast cancer patients treated with trastuzumab. Cancer Res.
75:2015. View Article : Google Scholar
|
|
6
|
Mittendorf EA, Clifton GT, Holmes JP,
Clive KS, Patil R, Benavides LC, Gates JD, Sears AK, Stojadinovic
A, Ponniah S and Peoples GE: Clinical trial results of the
HER-2/neu (E75) vaccine to prevent breast cancer recurrence in
high-risk patients: From US Military Cancer Institute Clinical
Trials Group Study I-01 and I-02. Cancer. 118:2594–2602. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Holder AM, Gonzalez-Angulo AM, Chen H,
Akcakanat A, Do KA, Symmans W Fraser, Pusztai L, Hortobagyi GN,
Mills GB and Meric-Bernstam F: Increased stearoyl-CoA desaturase 1
expression is associated with shorter survival in breast cancer
patients. Cancer Res. 137:319–327. 2013.
|
|
8
|
Glazko GV and Emmert-Streib F: Unite and
conquer: Univariate and multivariate approaches for finding
differentially expressed gene sets. Bioinformatics. 25:2348–2354.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Khatri P, Sirota M and Butte AJ: Ten years
of pathway analysis: Current approaches and outstanding challenges.
PLoS Comput Biol. 8:e10023752012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ahn T, Lee E, Huh N and Park T:
Personalized identification of altered pathways in cancer using
accumulated normal tissue data. Bioinformatics. 30:i422–i429. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen DT, Nasir A, Culhane A, Venkataramu
C, Fulp W, Rubio R, Wang T, Agrawal D, McCarthy SM, Gruidl M, et
al: Proliferative genes dominate malignancy-risk gene signature in
histologically-normal breast tissue. Breast Cancer Res Treat.
119:335–346. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Croft D, O'Kelly G, Wu G, Haw R, Gillespie
M, Matthews L, Caudy M, Garapati P, Gopinath G, Jassal B, et al:
Reactome: A database of reactions, pathways and biological
processes. Nucleic Acids Res. 39(Database issue): D691–D697. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Irizarry RA, Bolstad BM, Collin F, Cope
LM, Hobbs B and Speed TP: Summaries of Affymetrix GeneChip probe
level data. Nucleic Acids Res. 31:e152003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bolstad BM, Irizarry RA, Astrand M and
Speed TP: A comparison of normalization methods for high density
oligonucleotide array data based on variance and bias.
Bioinformatics. 19:185–193. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bolstad B: Affy: Built-in Processing
Methods. 2013.
|
|
16
|
Gehan EA: A Generalized Wilcoxon test for
comparing arbitrarily singly-censored samples. Biometrika.
52:203–223. 1965. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mohammadi A, Saraee MH and Salehi M:
Identification of disease-causing genes using microarray data
mining and Gene Ontology. BMC Med Genomics. 4:122011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Smyth GK: Linear models and empirical
bayes methods for assessing differential expression in microarray
experiments. Stat Appl Genet Mol Biol. 3:32004. View Article : Google Scholar
|
|
19
|
da W Huang, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2008. View Article : Google Scholar
|
|
20
|
Wang X and Simon R: Microarray-based
cancer prediction using single genes. BMC Bioinformatics.
12:3912011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rath O and Kozielski F: Kinesins and
cancer. Nat Rev Cancer. 12:527–539. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hirokawa N: Kinesin superfamily motor
proteins and intracellular transport. Nat Rev Mol Cell Biol.
10:682–696. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sharp DJ, Rogers GC and Scholey JM:
Microtubule motors in mitosis. Nature. 407:41–47. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rath O and Kozielski F: Kinesins and
cancer. Nat Rev Cancer. 12:527–539. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
De S, Cipriano R, Jackson MW and Stark GR:
Overexpression of kinesins mediates docetaxel resistance in breast
cancer cells. Cancer Res. 69:8035–8042. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tan MH, De S, Bebek G, Orloff MS,
Wesolowski R, Downs-Kelly E, Budd GT, Stark GR and Eng C: Specific
kinesin expression profiles associated with taxane resistance in
basal-like breast cancer. Breast Cancer Res Treat. 131:849–858.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zou JX, Duan Z, Wang J, Sokolov A, Xu J,
Chen CZ, Li JJ and Chen HW: Kinesin family deregulation coordinated
by bromodomain protein ANCCA and histone methyltransferase MLL for
breast cancer cell growth, survival, and tamoxifen resistance. Mol
Cancer Res. 12:539–549. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guerrero-Preston R, Hadar T, Ostrow KL,
Soudry E, Echenique M, Ili-Gangas C, Pérez G, Perez J,
Brebi-Mieville P, Deschamps J, et al: Differential promoter
methylation of kinesin family member 1a in plasma is associated
with breast cancer and DNA repair capacity. Oncol Rep. 32:505–512.
2014.PubMed/NCBI
|
|
29
|
Wang J, Ma S, Ma R, Qu X, Liu W, Lv C,
Zhao S and Gong Y: KIF2A silencing inhibits the proliferation and
migration of breast cancer cells and correlates with unfavorable
prognosis in breast cancer. BMC Cancer. 14:4612014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Khongkow P, Gomes A, Gong C, Man EP, Tsang
JW, Zhao F, Monteiro LJ, Coombes RC, Medema RH, Khoo US and Lam EW:
Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe
and breast cancer paclitaxel resistance. Oncogene. 35:990–1002.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Valensin S, Ghiron C, Lamanna C, Kremer A,
Rossi M, Ferruzzi P, Nievo M and Bakker A: KIF11 inhibition for
glioblastoma treatment: Reason to hope or a struggle with the
brain? BMC Cancer. 9:1962009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sumara I, Vorlaufer E, Stukenberg PT, Kelm
O, Redemann N, Nigg EA and Peters JM: The dissociation of cohesin
from chromosomes in prophase is regulated by Polo-like kinase. Mol
Cell. 9:515–525. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ha G, Kim H, Go H, Lee H, Seimiya H, Chung
DH and Lee CW: Tankyrase-1 function at telomeres and during mitosis
is regulated by Polo-like kinase-1-mediated phosphorylation. Cell
Death Differ. 19:321–332. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
von Schubert C and Nigg EA: Polo-like
kinases. Current Biol. 23:R225–R227. 2013. View Article : Google Scholar
|
|
35
|
Spänkuch-Schmitt B, Bereiter-Hahn J,
Kaufmann M and Strebhardt K: Effect of RNA silencing of polo-like
kinase-1 (PLK1) on apoptosis and spindle formation in human cancer
cells. J Natl Cancer Inst. 94:1863–1877. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Maire V, Némati F, Richardson M,
Vincent-Salomon A, Tesson B, Rigaill G, Gravier E, Marty-Prouvost
B, De Koning L, Lang G, et al: Polo-like kinase 1: A potential
therapeutic option in combination with conventional chemotherapy
for the management of patients with triple-negative breast cancer.
Cancer Res. 3:813–823. 2013. View Article : Google Scholar
|
|
37
|
Wierer M, Verde G, Pisano P, Molina H,
Font-Mateu J, Di Croce L and Beato M: PLK1 signaling in breast
cancer cells cooperates with estrogen receptor-dependent gene
transcription. Cell Rep. 27:2021–2032. 2013. View Article : Google Scholar
|
|
38
|
Strebhardt K and Ullrich A: Targeting
polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 6:321–330.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Strebhardt K: Multifaceted polo-like
kinases: Drug targets and antitargets for cancer therapy. Nat Rev
Drug Discov. 9:643–660. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Salvi M, Trashi E, Cozza G, Negro A,
Hanson PI and Pinna LA: Tools to discriminate between targets of
CK2 vs PLK2/PLK3 acidophilic kinases. Biotechniques.
53:2012.PubMed/NCBI
|
|
41
|
Salvi M, Trashi E, Cozza G, Franchin C,
Arrigoni G and Pinna L: Investigation on PLK2 and PLK3 substrate
recognition. Biochim Biophys Acta. 1824:1366–1373. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
King SI, Purdie CA, Bray SE, Quinlan PR,
Jordan LB, Thompson AM and Meek DW: Immunohistochemical detection
of Polo-like kinase-1 (PLK1) in primary breast cancer is associated
with TP53 mutation and poor clinical outcom. Breast Cancer Res.
14:R402012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Iyer RS, Nicol SM, Quinlan PR, Thompson
AM, Meek DW and Fuller-Pace FV: The RNA helicase/transcriptional
co-regulator, p68 (DDX5), stimulates expression of oncogenic
protein kinase, Polo-like kinase-1 (PLK1), and is associated with
elevated PLK1 levels in human breast cancers. Cell Cycle.
13:1413–1423. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Weichert W, Kristiansen G, Winzer KJ,
Schmidt M, Gekeler V, Noske A, Müller BM, Niesporek S, Dietel M and
Denkert C: Polo-like kinase isoforms in breast cancer: Expression
patterns and prognostic implications. Virchows Archiv. 446:442–450.
2005. View Article : Google Scholar : PubMed/NCBI
|
